Noninvasive imaging of receptor function: Signal transduction pathways and physiological readouts

Current Opinion in Drug Discovery and Development

Volumn 11, Issue 5, 2008, Pages 606-615

  Rudin, M ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Molecular imaging; Protein protein interaction; Reporter gene assay; Signal transduction pathways

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; ETOPOSIDE; FLUORESCENT DYE; MAMMALIAN TARGET OF RAPAMYCIN; MYOD PROTEIN; PROTEIN P53; RADIOISOTOPE; TRANSCRIPTION FACTOR GAL4; VIRUS LARGE T ANTIGEN;

BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CELL MEMBRANE; FLUORESCENCE RESONANCE ENERGY TRANSFER; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC ENGINEERING; HUMAN; IMAGING SYSTEM; MEDICAL RESEARCH; MOLECULAR IMAGING; NON INVASIVE MEASUREMENT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN DETERMINATION; PROTEIN FRAGMENT COMPLEMENTATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REPORTER GENE; REVIEW; SECOND MESSENGER; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TWO HYBRID SYSTEM;

ANIMALS; BINDING SITES; DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR PROBE TECHNIQUES; MOLECULAR PROBES; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; TECHNOLOGY, PHARMACEUTICAL;

EID: 50249130298     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Liu L, Simon MC: Regulation of transcription and translation by hypoxia. Cancer Biol Ther (2004) 3(6):492-497.
2. Rudin M: Molecular Imaging - Basic Principles and Applications in Biomedical Research. Imperial College Press, London, UK (2005). •• Textbook describing molecular imaging techniques, the development of imaging assays that are suitable for in vivo imaging and their application in biomedical research.
3. Villalobos V, Naik S, Piwnica-Worms D: Current state of imaging protein-protein interactions in vivo with genetically encoded reporters. Annu Rev Biomed Eng (2007) 9:321-349. • Comprehensive review describing the use of in vivo imaging assays to probe protein-protein interactions.
4. Tung CH, Mahmood U, Bredow S, Weissleder R: In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res (2000) 60(17):4953-4958. • Describes a target-activatable imaging probe and its application to monitor protease activity in tumors.
5. Förster T: Intermolecular energy migration and fluorescence. Ann Phys (Leipzig) (1948) 2:55-75.
6. Clegg RM: Fluorescence resonance energy transfer and nucleic acids. Meth Enzymol (1992) 211:353-388.
7. Weiss S: Measuring conformational dynamics of biomolecules by single molecule fluorescence spectroscopy. Nat Struct Biol (2000) 7(9):724-729.
8. De A, Gambhir SS: Noninvasive imaging of protein-protein interactions from live cells and living subjects using bioluminescence resonance energy transfer. FASEB J (2005) 19(14):2017-2019.
9. De A, Loening AM, Gambhir SS: An improved bioluminescence resonance energy transfer strategy for imaging intracellular events in single cells and living subjects. Cancer Res (2007) 67(15):7175-7183.
10. Fields S, Song O: A novel genetic system to detect protein-protein interactions. Nature (1989) 340(6230):245-246. • Introduces the two-hybrid system to investigate protein-protein interactions in cells.
11. Ozawa T, Umezawa Y: Detection of protein-protein interactions in vivo based on protein splicing. Curr Opin Chem Biol (2001) 5(5):578-583.
12. Ray P, Pimenta H, Paulmurugan R, Berger F, Phelps ME, Iyer M, Gambhir SS: Noninvasive quantitative imaging of protein-protein interactions in living subjects. Proc Natl Acad Sci USA (2002) 99(5):3105-3110.
13. Luker GD, Sharma V, Pica CM, Dahlheimer JL, Li W, Ochesky J, Ryan CE, Piwnica-Worms H, Piwnica-Worms D: Noninvasive imaging of protein-protein interactions in living animals. Proc Natl Acad Sci USA (2002) 99(10):6961-6966.
14. Gilad AA, Winnard PT Jr, van Zijl PC, Bulte JW: Developing MR reporter genes: Promises and pitfalls. NMR Biomed (2007) 20(3):275- 290.
15. Johnsson N, Varshavsky A: Split ubiquitin membrane-based yeast two hybrid system. Proc Natl Acad Sci USA (1994) 91(22):10340- 10344.
16. Stagljar I, Korostensky C, Johnsson N, te Heesen S: A genetic system based on split-ubiquitin for the analysis of interactions between membrane proteins in vivo. Proc Natl Acad Sci USA (1998) 95(9):5187-5192.
17. Michnick SW: Exploring protein interactions by interaction-induced folding of proteins from complementary peptide fragments. Curr Opin Struct Biol (2001) 11(4):472-477.
18. Paulmurugan R, Umezawa Y, Gambhir SS: Noninvasive imaging of protein-protein interactions in living subjects by using reporter protein complementation and reconstitution strategies. Proc Natl Acad Sci USA (2002) 99(24):15608-15613.
19. Paulmurugan R, Gambhir SS: Monitoring protein-protein interactions using split synthetic renilla luciferase protein-fragment-assisted complementation. Anal Chem (2003) 75(7):1584-1589.
20. Luker GD, Sharma V, Piwnica-Worms D: Visualizing protein-protein interactions in living animals. Meth Enzymol (2003) 29(1):110-122. • A comprehensive review of the use of imaging assays to probe protein-protein interactions.
21. Belshaw PJ, Ho SN, Crabtree GR, Schreiber SL: Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. Proc Natl Acad Sci USA (1996) 93(10):4604-4607.
22. Crabtree GR, Schreiber SL: Three-part inventions: Intracellular signaling and induced proximity. Trends Biochem Sci (1996) 21(11):418-422.
23. Paulmurugan R, Massoud T, Huang J, Gambhir SS: Molecular imaging of drug-modulated protein-protein interactions in living subjects. Cancer Res (2004) 64(6):2113-2119. • Describes the bioluminescence assay used to monitor rapamycin-induced protein-protein interactions.
24. Luker KE, Smith MC, Luker GD, Gammon ST, Piwnica-Worms H, Piwnica-Worms D: Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and live animals. Proc Natl Acad Sci USA (2004) 101(33):12288-12293.
25. Laxman B, Hall DE, Bhojani MS, Hamstra DA, Chevenert TL, Ross BD, Rehemtulla A: Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci USA (2002) 99(26):16551-16555.
26. Berger AB, Witte MD, Denault JB, Sadaghiani AM, Sexton KM, Salvesen GS, Bogyo M: Identification of early intermediates of caspase activation using selective inhibitors and activity-based probes. Mol Cell (2006) 23(4):509-521.
27. Kato D, Boatright KM, Berger AB, Nazif T, Blum G, Ryan C, Chehade KA, Salvesen GS, Bogyo M: Activity-based probes that target diverse cysteine protease families. Nat Chem Biol (2005) 1(1):33-38.
28. Fox PT, Raichle ME, Mintun MA, Dence C: Nonoxidative glucose consumption during focal physiologic neural activity. Science (1988) 241(4864):462-464.
29. Buxton RB, Frank LR: A model for the coupling between cerebral blood flow and oxygen metabolism during neural stimulation. J Cereb Blood Flow Metab (1997) 17(1):64-72.
30. Reese T, Bjelke B, Porszasz R, Baumann D, Bochelen D, Sauter A, Rudin M: Regional brain activation by bicuculline visualized by functional magnetic resonance imaging. Time resolved assessment of bicuculline-induced changes in local cerebral blood volume using an intravascular contrast agent. NMR Biomed (2000) 13(1):43-49.
31. Xu H, Li SJ, Bodurka J, Zhao X, Xi ZX, Stein EA: Heroin-induced neuronal activation in rat brain assessed by functional MRI. NeuroReport (2000) 11(5):1085-1092.
32. Gozzi A, Large CH, Schwarz A, Bertani S, Crestan V, Bifone A: Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology (2008) 33(7):1690-1703.
33. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, McIntyre D et al: The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations. Br J Cancer (2005) 92(9):1599-1610. • Recommends the use of imaging biomarkers for the assessment of anti-angiogenic drug efficacy.
34. Rudin M, McSheehy PM, Allegrini PR, Rausch M, Baumann D, Becquet M, Brecht K, Brueggen J, Ferretti S, Schaeffer F, Schnell C et al: PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumors and inhibits their growth in vivo. NMR Biomed (2005) 18(5):308-321.
35. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W et al: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol (2003) 21(21):3955-3964.
36. Drevs J, Schneider V: The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis. J Intern Med (2006) 260(6):517-529.
37. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl. J Exp Med (1995) 182(5):1545-1556. • Describes the redistribution of phosphatidylserine to the outer leaflet of the cell membrane during apoptosis, which therefore constitutes an attractive target for apoptosis assays.
38. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, Kopiwoda S, Abrams MJ, Darkes M, Robbins RC, Maecker HT et al: In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA (1998) 95(11):6349-6354.
39. Schellenberger EA, Bogdanov A Jr, Petrovsky A, Ntziachristos V, Weissleder R, Josephson L: Optical imaging of apoptosis as a biomarker of tumor response to chemotherapy. Neoplasia (2003) 5(3):187-192.
40. Zhao M, Beauregard DA, Loizou L, Davletov B, Brindle KM: Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med (2001) 7(11):1241-1244.
41. Berridge MJ, Irvine RF: Inositol phosphates and cell signalling. Nature (1989) 341(6239):197-205.
42. 31P NMR spectroscopy of agonist-stimulated phosphatidyl-inositol metabolism in cat brain. Magn Reson Med (1987) 4(3):221-226.
43. Nunes RA, Harris LN: The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer (2002) 3(2):125-135.
44. US Food and Drug Administration: Innovation/stagnation: Challenge and opportunity on the critical path to new medical products. Press Release (2004) March 16. www.fda.gov/oc/initiatives/criticalpath/ whitepaper.html •• The FDA Critical Path initiative addresses issues in the current drug discovery and development process and proposes solutions to accelerate drug development.
45. Rudin M: Imaging readouts as biomarkers or surrogate parameters for the assessment of therapeutic interventions. Eur Radiol (2007) 17(10):2441-2457. •• Describes the opportunities and issues of using imaging-based biomarkers in drug discovery and development.
46. Drews J: Drug discovery: A historical perspective. Science (2000) 287(5460):1960-1964.